Analysts Unconvinced By Sanofi Best-In-Class Claims For Sarclisa
Much Ground To Make Up On J&J's Darzalex
Sanofi presented new data at a post-ASCO briefing to back its claim that Sarclisa can become the anti-CD38 of choice for the treatment of multiple myeloma ahead of Darzalex. The investment community is not so sure.
You may also be interested in...
NICE is not yet convinced that Sanofi’s recently approved combination treatment for relapsed or refractory multiple myeloma is value for money. Temporary funding under the Cancer Drugs Fund has also been ruled out.
The gap between potential approvals for Bristol’s ide-cel and Janssen’s JNJ-4528 has narrowed as both CAR-T therapies show high response rates in multiple myeloma – and as bispecific antibodies, including Janssen’s teclistamab, edge into the space.
The Danish biotech will be getting more revenues from its J&J-partnered multiple myeloma blockbuster following a new US approval. Analysts are impressed with the way Genmab is spending the money.